<DOC>
	<DOC>NCT02974504</DOC>
	<brief_summary>A multi-center, randomized, double-blind, active-controlled, parallel group, phase IV clinical trial to investigate the effect on blood glucose of evogliptin after oral administration in patients with type 2 diabetes</brief_summary>
	<brief_title>Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description>1. Evogliptin 5mg Group: Administration with Evogliptin 5mg for 0-24 weeks. 2. Liniagliptin 5mg Group: Administration with linagliptin 5mg for 0-12 weeks, and with Evogliptin 5mg for 13-24 weeks</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Subjects with 7.0%≤HbA1c≤10.0% at screening Subjects untreated with oral hypoglycemic agents within 8 weeks prior to screening Subjects with 20kg/m2≤BMI≤40kg/m2 at screening Subjects with fasting plasma glucose≥270mg/dL at screening Patients with type 1 diabetes mellitus, secondary diabetes mellitus or gestational diabetes mellitus Subjects with history of myocardial infarction, cerebral infarction within 24 weeks prior to screening Subjects with ALT and AST 3 times or higher than upper normal range</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>